Modulation of MMP-2 and MMP-9 secretion by cytokines, inducers and inhibitors in human glioblastoma T-98G cells

Oncology Reports

Volumn 37, Issue 3, 2017, Pages 1907-1913

  Roomi, M Waheed ^a   Kalinovsky, Tatiana ^a   Rath, Matthias ^a   Niedzwiecki, Aleksandra ^a  

^a Dr Rath Research Institute   (United States)

Author keywords

Cytokines; Glioblastoma T 98G; Inducers; Inhibitors; Matrix metalloproteinases

Indexed keywords

ASCORBIC ACID; DACTINOMYCIN; DOXYCYCLINE; ENZYME INDUCING AGENT; ENZYME INHIBITOR; EPIGALLOCATECHIN GALLATE; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; LYSINE; PHORBOL 13 ACETATE 12 MYRISTATE; PROLINE; RETINOIC ACID; SINECATECHINS; TUMOR NECROSIS FACTOR; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CARCINOGEN; CATECHIN; CYTOKINE; ENZYME ACTIVATOR; MATRIX METALLOPROTEINASE INHIBITOR; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME RELEASE; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; T 98G CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; BOVINE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GLIOBLASTOMA; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL CULTURE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CARCINOGENS; CATECHIN; CATTLE; CYTOKINES; DOXYCYCLINE; ENZYME ACTIVATORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; TETRADECANOYLPHORBOL ACETATE; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85013324793     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2017.5391     Document Type: Article

References (42)

1. ACS: What are the key statistics about brain and spinal cord tumors? Last revised 1/21/2016. Accessed 9/15/16. http://www.cancer.org/cancer/braincnstumorsinadults/detailedguide/brain-and-spinalcord-tumors-in-adults-key-statistics.
2. ABTA (American Brain Tumor Association): Brain Tumor Facts. Last revised 12/2015. Accessed 9/15/16. http://www.abta.org/about-us/news/brain-tumor-statistics.
3. Yurchenco PD and Schittny JC: Molecular architecture of basement membranes. FASEB J 4: 1577-1590, 1990.
4. Barsky SH, Siegal GP, Jannotta F and Liotta LA: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 49: 140-147, 1983.
5. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
6. Forsyth PA, Laing TD, Gibson AW, Rewcastle NB, Brasher P, Sutherland G, Johnston RN and Edwards DR: High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma. J Neurooncol 36: 21-29, 1998.
7. Jäälinojä J, Herva R, Korpela M, Höyhtyä M and Turpeenniemi- Hujanen T: Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neurooncol 46: 81-90, 2000.
8. Smith ER, Zurakowski D, Saad A, Scott RM and Moses MA: Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 14: 2378-2386, 2008.
9. de Visser KE and Coussens LM: The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 13: 118-137, 2006.
10. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
11. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454: 436-444, 2008.
12. Germano G, Allavena P and Mantovani A: Cytokines as a key component of cancer-related inflammation. Cytokine 43: 374-379, 2008.
13. Allavena P, Garlanda C, Borrello MG, Sica A and Mantovani A: Pathways connecting inflammation and cancer. Curr Opin Genet Dev 18: 3-10, 2008.
14. Gridley DS, Loredo LN, Slater JD, Archambeau JO, Bedros AA, Andres ML and Slater JM: Pilot evaluation of cytokine levels in patients undergoing radiotherapy for brain tumor. Cancer Detect Prev 22: 20-29, 1998.
15. Zhou W, Jiang Z, Li X, Xu Y and Shao Z: Cytokines: Shifting the balance between glioma cells and tumor microenvironment after irradiation. J Cancer Res Clin Oncol 141: 575-589, 2015.
16. Ilyin SE, González-Gómez I, Romanovicht A, Gayle D, Gilles FH and Plata-Salamán CR: Autoregulation of the interleukin-1 system and cytokine-cytokine interactions in primary human astrocytoma cells. Brain Res Bull 51: 29-34, 2000.
17. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K and Kuwano M: Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 271: 28220-28228, 1996.
18. Esteve PO, Tremblay P, Houde M, St-Pierre Y and Mandeville R: In vitro expression of MMP-2 and MMP-9 in glioma cells following exposure to inflammatory mediators. Biochim Biophys Acta 1403: 85-96, 1998.
19. Niedzwiecki A, Roomi MW, Kalinovsky T and Rath M: Micronutrient synergy - a new tool in effective control of metastasis and other key mechanisms of cancer. Cancer Metastasis Rev 29: 529-542, 2010.
20. Rath M and Pauling L: Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic analogs. Orthomolecular Med 7: 17-23, 1992.
21. Sun Z, Chen YH, Wang P, Zhang J, Gurewich V, Zhang P and Liu JN: The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta 1596: 182-192, 2002.
22. Mussini E, Hutton JJ Jr and Udenfriend S: Collagen proline hydroxylase in wound healing, granuloma formation, scurvy, and growth. Science 157: 927-929, 1967.
23. Kivirikko KI and Myllylä R: Collagen glycosyltransferases. Int Rev Connect Tissue Res 8: 23-72, 1979.
24. Valcic S, Timmermann BN, Alberts DS, Wächter GA, Krutzsch M, Wymer J and Guillén JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs 7: 461-468, 1996.
25. Mukhtar H and Ahmad N: Tea polyphenols: Prevention of cancer and optimizing health. Am J Clin Nutr 71 (Suppl 6): S1698S-S1704S, 2000.
26. Yang GY, Liao J, Kim K, Yurkow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19: 611-616, 1998.
27. Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H and Shimokawa R: Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65: 51-54, 1992.
28. Hara Y: Green Tea: Health Benefits and Applications. Marcel Dekker, New York, Basel, 2001. http://dx.doi.org/10.1201/9780203907993.
29. Gupta S, Hastak K, Afaq F, Ahmad N and Mukhtar H: Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene 23: 2507-2522, 2004.
30. Fujiki H, Suganuma M, Okabe S, Sueoka E, Suga K, Imai K, Nakachi K and Kimura S: Mechanistic findings of green tea as cancer preventive for humans. Proc Soc Exp Biol Med 220: 225-228, 1999.
31. Kawakami S, Kageyama Y, Fujii Y, Kihara K and Oshima H: Inhibitory effect of N-acetylcysteine on invasion and MMP-9 production of T24 human bladder cancer cells. Anticancer Res 21: 213-219, 2001.
32. Morini M, Cai T, Aluigi mg, Noonan DM, Masiello L, De Flora S, D'Agostini F, Albini A and Fassina G: The role of the thiol N-acetylcysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers 14: 268-271, 1999.
33. Yoon SO, Kim MM and Chung AS: Inhibitory effect of selenite on invasion of HT1080 tumor cells. J Biol Chem 276: 20085-20092, 2001.
34. Cha J, Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C-deficient mice. Int J Oncol 42: 55-64, 2013.
35. Naidu KA, Karl RC, Naidu KA and Coppola D: Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: Association with decreased expression of insulin-like growth factor 1 receptor. Dig Dis Sci 48: 230-237, 2003.
36. Anthony HM and Schorah CJ: Severe hypovitaminosis C in lung-cancer patients: The utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer 46: 354-367, 1982.
37. Maramag C, Menon M, Balaji KC, Reddy PG and Laxmanan S: Effect of vitamin C on prostate cancer cells in vitro: Effect on cell number, viability, and DNA synthesis. Prostate 32: 188-195, 1997.
38. Koh WS, Lee SJ, Lee H, Park C, Park MH, Kim WS, Yoon SS, Park K, Hong SI, Chung MH, et al: Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res 18: 2487-2493, 1998.
39. Chen Q, Espey mg, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102: 13604-13609, 2005.
40. Núñez Martín C, Ortiz de Apodaca y Ruiz A and Ruiz A: Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of the consumption of food with an elevated content of this vitamin. Nutr Hosp 10: 368-372, 1995 (In Spanish).
41. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103: 183-189, 1996.
42. Cooke JP and Dzau VJ: Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med 48: 489-509, 1997.